Skip to main content
PLOS Pathogens logoLink to PLOS Pathogens
. 2025 Oct 27;21(10):e1013607. doi: 10.1371/journal.ppat.1013607

Flavin affinity for the reductase HpaC differentially sensitizes Neisseria gonorrhoeae during Type IV pilus-dependent killing

Linda I Hu 1,*, Egon A Ozer 2, H S Seifert 1
Editor: William M Shafer3
PMCID: PMC12558477  PMID: 41144484

Abstract

The Neisseria gonorrhoeae Type IV pilus is a dynamic fiber involved in host cell attachment, DNA transformation, twitching motility, and evading the innate immune system. We previously reported that pilus expression affects iron homeostasis and sensitivity to killing by oxidative (iron-dependent antibiotic streptonigrin and hydrogen peroxide and non-oxidative (antimicrobial peptide LL-37) agents. Here, we use in vitro evolution to identify genes involved in N. gonorrhoeae susceptibility to streptonigrin. We identified a mutation in the NGO0059 locus that encodes HpaC that results in a glycine to cysteine change in position 93. Although HpaC homologs are known as part of a two-component FAD-dependent monooxygenase system consisting of an hpaC reductase and an hpaB monooxygenase, Neisseria lack the monooxygenase. While HpaC increases streptonigrin sensitivity, HpaC also promotes hydrogen peroxide and LL-37 resistance. We tested whether the HpaC effect in streptonigrin, hydrogen peroxide and LL-37 sensitivity involved the Type IV pilus. We determined that HpaC affects streptonigrin independently of the pilus while hydrogen peroxide- and LL-37-mediated killing involves both HpaC and the pilus. We demonstrate that the Gly93Cys change conferred enhanced affinity for FAD and resulted in a loss-of-function phenotype in streptonigrin susceptibility. These data suggest that HpaC’s role in FAD oxidation and reduction impacts pilus-dependent and -independent resistance against neutrophil-mediated killing.

Author summary

Neisseria gonorrhoeae is the causative agent of the sexually transmitted disease, gonorrhea. Neutrophils are first host immune responders that activate multiple potent antimicrobial defences including reactive oxygen species and antimicrobial peptides. Yet, N. gonorrhoeae is highly resistant to these host protection mechanisms. The Type IV pilus is known to promote resistance to these antibacterial agents; however, how the pilus does this was not known. We show that an FAD reductase HpaC has pilus-dependent and pilus-independent functions that contribute to this bacterium’s resistance through its interaction with flavin.

Introduction

Neisseria gonorrhoeae (Gc, gonococcus) is the causative agent of gonorrhea, the second leading bacterial sexually transmitted infection behind chlamydia. Gc colonizes the urogenital tract and can cause epididymitis in men and pelvic inflammatory disease in women [1]. If left untreated, the infection can lead to complications of ectopic pregnancy, infertility, neonatal blindness, arthritis and, in extreme cases, sepsis [24].

As Gc do not express exotoxins, colonization drives pathology by increasing local inflammation. Mucosal epithelial cells and macrophage pattern recognition of shed peptidoglycan fragments and components of the outer membrane trigger neutrophil recruitment to the site of infection [5,6]. The Gc surface opacity proteins bind to the human neutrophil receptor CEACAM3 and activate a signaling cascade resulting in the further release of neutrophil recruiting cytokines [7]. This forward-feeding circuit continues, amplifying the inflammatory response. While neutrophil activation fights the infection, tissue damage also occurs. As a result, neutrophils play a key role in Gc pathogenesis.

Despite these waves of incoming neutrophils, they do not clear Gc infections. During an oxidative burst, the enzyme complex NADPH oxidase assembles on the neutrophil phagosomal and plasma membranes and converts oxygen to superoxide and secondary ROS, which includes hydrogen peroxide (H2O2). ROS oxidize and damage DNA, lipids, proteins and iron-sulfur clusters [8]. Neutrophils also release their genomic DNA in a process called NETosis that encases bacterial cells in a mesh. NETosis and degranulation release degradative enzymes like proteases and lysozyme and cationic antimicrobial peptide LL-37 [9] which target and perforate the bacterial membrane [10]. Nonetheless, neutrophil-rich secretions carry viable Gc that can survive within neutrophils due to Gc expressing factors that resist neutrophil antimicrobials [1118], one of which is the Type IV pilus (T4p) [19]. The T4p is a dynamic fiber that can extend and retract through its assembly and disassembly. T4p is selected for in experimental infections [20,21] and is essential for multiple functions, including colonization, adherence to the host epithelium, twitching motility on surfaces [22], formation of cell aggregates with neighboring Gc [23], and transformation of extracellular DNA [24].

The most recent T4p function reported was promoting resistance to neutrophil-mediated killing [25]. In the absence of the gene pilE that encodes the major pilus subunit, pilin, Gc cells are sensitive to antimicrobial peptide LL-37 and H2O2 [25]. Using the bactericidal antibiotic streptonigrin (SPN), we determined that the mechanism of pilus-mediated resistance to neutrophils involves iron homeostasis [19]. The soil bacterium Streptomyces flocculus produces SPN which binds to labile intracellular iron, interacts with DNA and locally generates reactive oxygen species [26]. Resistance to SPN, H2O2, and LL-37 was restored to the ΔpilE mutant when iron was limited [19]. Here, we used in vitro evolution to isolate nonpiliated Gc mutants with increased SPN resistance. This approach led us to discover a role for an FAD reductase HpaC in SPN resistance previously known for its role in aromatic compound metabolism.

Results

In vitro evolution of pilE mutant to increase SPN resistance

We previously reported that a ΔpilE mutant (N-1–69, Table 1) was more sensitive to SPN than the FA1090 parental strain N-1–60 [19]. To identify genes involved in SPN sensitivity, we performed in vitro evolution of a Gc pilE mutant to increase SPN resistance. We treated a mid-exponential phase ΔpilE Gc culture with 0.5 µM SPN for 30 minutes. This SPN treatment dose and duration results in the relative survival of between 10-2 to 10-3 ΔpilE cells compared to ≥10-1 piliated, parental cells. After six sequential rounds of growth and SPN selection, we tested 16 isolates to determine whether the population demonstrated an increased level of SPN resistance compared to the unevolved ΔpilE parental strain. We observed increased resistance compared to the control strain for all the isolates (Fig 1A). Whole genome sequencing and variant calling of two of these isolates showed eight genetic changes (S1 Table) compared to an unevolved strain. Six intragenic mutations (a missense mutation in NGO0059 hpaC, a synonymous mutation in NGO0650 recN, and phase variations in NGO11100 opaB, NGO09965 opaE, NGO1765 pglA, and NGO2158 lgtD) and two intergenic phase variations (one between NGO2093 fetA and NGO02094 groES and another between NGO1810 hypothetical gene and NGO1811 truA).

Table 1. Strains and plasmids.

Strain or plasmid Description Reference/source
Strains
N-1–60 FA1090 multisite G4 mutant 1–81-S2 pilE variant, pilC1PL Hu and Yin et al 2020
N-1–69 An unmarked ΔpilE mutant (deletion from the 6th amino acid to the stop codon in pilE from Alison Criss) in N-1–60 Hu and Yin et al 2020
N-5–22 CRISPRi-pilE in N-1–60 Geslewitz et al 2023
N-7–15 hpaC(Gly93Cys) point mutation in N-5–22 this study
N-7–37 ΔhpaC::kan mutation in N-1–60 this study
N-7–52 ΔpilE (N-1–69) in N-7–37 this study
N-8–53 N-8–57 with IPTG-inducible hpaC cloned in the lctP/aspC nics chromosomal region this study
N-8–57 In-frame replacement of hpaC ORF with 18 bp EcoR1-EcoRV-BamH1 polylinker complemented with hpaC in the nics site, ErmR this study
N-8–63 N-8–65 with IPTG-inducible hpaC cloned in the lctP/aspC nics chromosomal region this study
N-8–65 unmarked ΔpilE mutant from N-1–69 in N-8–57 this study
N-9–38 N-8–57 with IPTG-inducible hpaC(Gly93Cys) cloned in the lctP/aspC nics chromosomal region this study
N-9–1 N-8–57 with IPTG-inducible hpaC(Gly93Ala) cloned in the lctP/aspC nics chromosomal region this study
Plasmids
pET28a-FA1090-HpaC pET28a plasmid carrying hpaC [NGO0059], KanR this study
pET28a-FA1090-HpaC(Gly93Cys) pET28a plasmid carrying hpaC with a G277-T277 mutation, KanR this study
pGCC4 IPTG-inducible Neisseria chromosomal complementation (nics) vector, KanR and ErmR Mehr and Seifert 1998
pGCC4-FA1090-HpaC pGCC4 plasmid with hpaC cloned into the PacI/PmeI site, KanR and ErmR this study
pGCC4-FA1090-HpaC(Gly93Cys) pGCC4 plasmid with hpaC(Gly93Cys) cloned into the PacI/PmeI site, KanR and ErmR this study

Fig 1. Using in vitro evolution to increase SPN resistance in the absence of pilin.

Fig 1

(A) A comparison of SPN sensitivity in the unevolved ΔpilE mutant (N-1-69) to 16 clones after in vitro evolution with streptonigrin. Significance was determined using a Student’s t test. Shown are the means and standard deviations. (B) Repressing pilE expression using an IPTG-inducible CRISPR interference system [27] reduces SPN resistance. The medians are shown for biological replicates. Statistical significance was determined using a one-way ordinary analysis of variance (ANOVA) followed by a Dunn’s multiple comparisons test. (C) SPN relative survival of four CRISPRi-pilE strains isolated from a backcross (Transformant 1, 2, 3, and 4) using genomic DNA from the evolved, SPN resistant ΔpilE mutant compared to the control CRISPRi-pilE strain (N-5-22) in the presence and absence of pilE repression using IPTG. The means of biological replicates and the standard error are plotted.

Isolating an hpaC point mutation that is responsible for SPN resistance

To discriminate between observed mutations that were responsible for SPN resistance and those unrelated to SPN sensitivity, we transformed the evolved strains’ genomic DNA into a strain that has conditional pilE expression using IPTG-regulated CRISPR interference (CRISPRi-pilE strain N-5–22, Table 1) [27]. As expected, CRISPRi-pilE exhibited an IPTG concentration-dependent sensitivity to SPN (Fig 1B). We treated the transformed cells with SPN in the presence (pilE is repressed) and absence of IPTG (pilE is expressed). Two transformants (T1 and T2 in Fig 1C) showed similar relative survival as the untransformed parental strain. Interestingly, two transformants (T3 and T4 in Fig 1C) were less sensitive to SPN than transformants T1 and T2.

We compared the genomic sequence of T3 and T4 to T1 and T2 (Table 2) and identified six mutations. One mutation was a nonsynonymous point mutation identified within the hpaC gene (NGO0057) in the SPN-resistant isolates T3 and T4. A G-to-T substitution at nucleotide position 277 results in a Gly-to-Cys change at amino acid position 93 of HpaC (Table 2). Five mutations were intergenic or intragenic variations of polynucleotide repeat numbers previously identified to undergo stochastic phase variation [2830]. However, these polynucleotides repeat variations were not specific to the resistant clones T3 and T4.

Table 2. Whole genome sequencing of SPN sensitive and resistant transformants.

Transformant
T1S T2S T3R T4R Mutation Gene [locus]
hpaC(Gly93) hpaC(Gly93) hpaC(Cys93) hpaC(Cys93) missense variant hpaC [NGO0059]
(G)14 → 13 (G)14 (G)14 (G)14 → 13 phase variant lgtC [NGO11620]
(G)13 (G)13 → 14 (G)13 → 12 (G)13 phase variant lgtD [NGO2158]
(CGCAA)14 → 16 (CGCAA)14 (CGCAA)14 (CGCAA)14 phase variant hypothetical [NGO0366]
(C)9 → 12 (C)9 → 10 (C)9 → 12 (C)9 → 12 intergenic phase variant fetA [NGO2093] - groES [NGO2094]
(C)10 (C)10 → 11 (C)10 → 11 (C)10 → 11 intergenic phase variant hypothetical [NGO1810] - truA [NGO1811]

Table 2 shows the whole genome comparison of four backcrossed strains.

“S” and “R” indicate whether the transformant (T) was relatively more resistant (R) or not (S) to streptonigrin than the parent strain CRISPRi-pilE (N-5–22) when pilE expression is repressed.

The arrows indicate the change in repeat number compared to the parent strain CRISPRi-pilE (N-5–22). No arrow indicates that the sequence did not change compared to the CRISPRi-pilE.

HpaC promotes SPN sensitivity independently of the T4p

To determine the role of HpaC in SPN resistance, we replaced the hpaC open reading frame with a kanamycin resistance cassette in piliated N-1–60 and nonpiliated ΔpilE backgrounds. The hpaC insertional mutant (Fig 2A) had a similar SPN phenotype to the Gly93Cys mutation (Fig 2B): deleting hpaC promoted SPN resistance in both piliated and nonpiliated cells and the effect was greater in nonpiliated Gc. We also complemented the hpaC null mutant in piliated (hpaC/nics::hpaC, N-8–53, Table 1, Fig 3A) and nonpiliated Gc (ΔpilEΔhpaC/nics::hpaC, N-8–63, Table 1, Fig 3B).

Fig 2. HpaC inhibits SPN survival in a T4p-independent manner.

Fig 2

(A) Testing the effect of a ΔhpaC mutation in piliated and non-piliated Gc on streptonigrin sensitivity. The relative survival of FA1090 (N-1-60), ΔhpaC (N-7-37), ΔpilE (N-1-69), and ΔpilEΔhpaC (N-7-52) to SPN. (B) The effect of repressing pilE expression in a strain that carries hpaC(Gly93Cys) on SPN sensitivity. CRISPRi-pilE (N-5-22) and CRISPRi-pilE/hpaC(Gly93Cys) (N-7-15) were treated with or without 1 mM IPTG to repress pilE expression and with or without 0.8 µM SPN. The average relative survival of biological replicates and standard errors are shown. An ANOVA was used to determine statistical significance in A and a two-way ANOVA for B.

Fig 3. ΔhpaC complementation and HpaC overexpression.

Fig 3

Complementing an ΔhpaC mutation in piliated and non-piliated FA1090. The effect of inducing hpaC expression with IPTG from the lctP/aspC nics region in the chromosome in (A) an ΔhpaC mutant (N-8-53) compared to the N-1-60 parent strain or in (B) a ΔpilEΔhpaC (N-8-63) mutant compared to a ΔpilE mutant on SPN sensitivity. (C) Overexpressing HpaC(Gly93Cys) has no effect on SPN sensitivity. Comparing the effect of ΔhpaC (N-8-57), ΔhpaC/nics::hpaC (N-8-53), ΔhpaC/nics::hpaC(Gly93Cys) (N-9-38), and ΔhpaC/nics::hpaC(Gly93Ala) (N-9-1) on SPN relative survival. The average relative survival and standard error of biological replicates are shown, and an ANOVA was used to determine the statistical significance.

The similar SPN sensitivity patterns between the deletion of hpaC and the hpaC(Gly93Cys) mutant suggested that hpaC(Gly93Cys) is a loss-of-function mutation. Consistent with this assertion, overexpressing WT hpaC inhibited SPN resistance while overexpressing hpaC(Gly93Cys) had no effect (Fig 3C). This residue is not critical for HpaC-mediated inhibition of SPN sensitivity because an hpaC(Gly93Ala) mutant partially complemented SPN resistance (Fig 3C). These results indicate that HpaC inhibits SPN resistance, HpaC functions independently of the T4p, and the Gly93Cys change is a loss-of-function mutation.

HpaC promotes LL-37 and H2O2 resistance

Since HpaC affects SPN resistance, we asked whether HpaC impacted other pilus-dependent phenotypes. We previously reported that T4p promotes resistance to LL-37 and H2O2 killing [19,25]. We deleted hpaC in piliated and nonpiliated Gc and measured the mutants’ relative survival to LL-37 and H2O2. While HpaC had no effect at lower concentrations of LL-37 or H2O2 (Fig 4, S1A, S1C Figs), at a higher LL-37 or H2O2 concentration, PilE and HpaC promoted resistance (Fig 4, S1B, and S1D). Interestingly, deleting both hpaC and pilE did not significantly affect their sensitivity to LL37 compared to the single mutants (Fig 4, S1A, S1B). While the double mutant was more sensitive to H2O2 than either single mutant (Figs 4B and S1D Figs), these differences were not statistically significant (p-value >0.99). Therefore, HpaC promotes LL-37 and H2O2 resistance and the mechanism is in a T4p-dependent manner.

Fig 4. HpaC promotes T4p-dependent resistance to higher concentrations of LL-37 and H2O2.

Fig 4

The relative survival of FA1090 (N-1-60), ΔhpaC (N-7-37), ΔpilE (N-1-69), and ΔpilEΔhpaC (N-7-52) to an LL-37 concentration gradient (A) or H2O2 concentration gradient (B). Ordinary one-way ANOVA was performed to determine statistical significance (* = p < 0.05, ** = p < 0.01, *** = p < 0.001). The standard error of the means are shown for at least five biological replicates in A and for at least nine biological replicates for each strain in B.

We also tested whether HpaC affects Gc sensitivity to other antimicrobials. We tested six other antibiotics that disrupt multiple cellular targets (cell wall synthesis: ampicillin, ceftazidime; cell envelope: polymyxin B; DNA replication: nalidixic acid; transcription: rifampicin; and translation: tetracycline) (S2 Fig). HpaC expression had no effect and, consistent with previous findings, piliation did not affect sensitivity to these antimicrobials [19].

The role of oxidative killing in HpaC-mediated SPN sensitivity

SPN kills Gc by reacting with intracellular labile iron and producing DNA-damaging reactive oxygen species [19,26,31]. This killing is reduced by the addition of superoxide scavenger tiron [19,32]. We tested the role of the reactive oxygen species inhibitor in HpaC-mediated SPN sensitivity by comparing the ΔpilE mutant with and without an hpaC mutation (S3 Fig). Consistent with what we observed previously, tiron partially restored resistance to SPN in a ΔpilE mutant [19]. Deleting hpaC in a ΔpilE mutant phenocopied this tiron-mediated partial restoration, suggesting that the deletion of hpaC resolves some but not all SPN-generated oxidants in the pilE mutant (S3 Fig). In a ΔpilEΔhpaC double mutant, tiron completely restored resistance to SPN (S3 Fig). These results indicate that ΔpilE SPN sensitivity is due to the combination of oxidative killing and the presence of HpaC.

HpaC Glycine-93 affects FAD affinity

To understand the effect of the Gly93Cys mutation on the HpaC protein, we determined the structural context of Gly93 by generating an AlphaFold structural model of HpaC. We aligned the peptide sequence of FA1090 HpaC to the structure of the FAD oxidoreductase TftC from Burkholderia cepacia (PDB 3K88 with a resolution of 2Å) that was crystallized with FAD and NADH [33] (Figs 5A and S4). TftC and HpaC are likely to be homologs with a Blast E-value of 1e-29. Gly93 is on an unstructured linker (Ala89-Glu97) between two alpha helices (Asp79-Phe88 and Glu98-Ala101) (Figs 5A and S4). This loop is one of the two conserved loops that form an FAD binding pocket in FAD oxidoreductases, the second linker being Arg58-Arg61 [33] (highlighted in S4 Fig). To determine whether HpaC interacts with FAD, we compared the level of FAD-dependent fluorescence in the purified protein with and without heat-denaturation using a probe-based assay that detects FAD [34]. We purified Gc HpaC and noticed an FAD signal in the absence of heat, indicating HpaC co-purified with FAD (Fig 5B). There was also an increase in the amount of detectable FAD following heat denaturation suggesting that HpaC can release bound FAD upon protein unfolding. We then tested the effect of Gly93Cys mutation on HpaC and FAD interaction. We determined that HpaC(Gly93Cys) bound significantly more FAD than WT HpaC (Fig 5C). Therefore, a Gly93 to Cys mutation enhances FAD affinity to HpaC.

Fig 5. HpaC(Gly93Cys) interacts with FAD better than WT HpaC.

Fig 5

(A) Gc HpaC structural modeling based on an alignment to B. cepacia TftC homodimer (PDB ID 3K88). FAD is magenta and NADH is green. Red and blue are the two HpaC monomers. (B) FAD-dependent fluorescence assays using 0.5 µM WT HpaC, with and without heat denaturation. (C) A comparison of bound FAD fluorescence between 5 nM WT HpaC and HpaC(Gly93Cys). An Analysis of Covariance (ANCOVA) was performed to determine statistical significance of the slopes (*** = p < 0.001). The means and standard errors of three technical replicates are plotted.

Presence of HpaB and HpaC homologs in bacteria is variable

HpaC is a flavin reductase that participates in 4-hydroxyphenylacetate (4HPA) metabolism [35]. 4HPA is a metabolic byproduct of aromatic amino acid and phenolic compound degradation and has been identified in human saliva [36]. HpaC is known to work with its partner protein, the monooxygenase HpaB [35,37]. HpaB receives two electrons from HpaC in the form of FADH2 for ortho-hydroxylation of 4HPA releasing 3,4-dihydroxyphenylacetate. HpaB and HpaC structure and function have been studied in several microorganisms, including E. coli strain W, Acinetobacter baumannii, Thermus thermophilus, Pseudomonas putida and aeruginosa, and Klebsiella pneumoniae [3849]. However, we could not identify an hpaB homolog in Gc or any other Neisseria species. We asked whether other bacterial species had an hpaC homolog without an hpaB homolog (Fig 6) using the National Center for Biotechnology Institute Gene database [50]. While nine Betaproteobacteria and 37 Gammaproteobacteria had both genes (hpaB + hpaC+), 15 Betaproteobacteria, including Neisseria, and 18 Gammaproteobacteria had hpaC without an hpaB gene (hpaC+). Additionally, a few genera (two Gammaproteobacteria and two Betaproteobacteria) had hpaB without an hpaC homolog (hpaB+). Therefore, Neisseria is not unique for only having HpaC and suggests that HpaC has functions independent of 4HPA metabolism in Neisseria and possibly other bacteria.

Fig 6. The presence of hpaB, hpaC, or both in classes Betaproteobacteria and Gammaproteobacteria.

Fig 6

Neighbor-joining phylogenetic tree using Betaproteobacteria (right-pointing arrow) and Gammaproteobacteria (left-pointing arrow) 16S rRNA gene sequences. Pink, grey, and blue arrows indicate genera with both hpaC and hpaB (hpaB + hpaC+), hpaC only (hpaC+), or hpaB only (hpaB+), respectively. (Not all E. coli strains contain hpaBC. E. coli B, C, and W have both genes in an operon while E. coli K-12 have neither gene [51,52].

We studied the phylogenetic distribution of the hpaB and hpaC genes to reveal possible mechanisms of evolution (Fig 6 ). We constructed a phylogenetic tree using 16S rRNA gene sequences. In clade I, gammaproteobacterial hpaB + hpaC+ genera dominate. However, two gammaproteobacterial genera, Morganella and Proteus, are hpaC+ in Clade I, suggesting that hpaB gene loss occurred within these two organisms. Clade II consists mostly of hpaC+ genera apart from three hpaB + hpaC+ gammaproteobacterial genera, Conservatibacter, Pasteurella, and Lonepinella. Clades III and IV are mixed. Clade III consists of 11 hpaB + hpaC + , 16 hpaC + , and two hpaB+ genera and clade IV consists of three hpaB + hpaC + , two hpaC + , and two hpaB+ genera. This distribution of hpaB and hpaC suggests that multiple independent gene loss events occurred during evolution.

Discussion

We previously reported that a ΔpilE mutant is hypersensitive to SPN, LL-37, and H2O2 compared to an isogenic, piliated strain in an iron-dependent manner [19]. Here, we show that in vitro evolution of a ΔpilE mutant to increased SPN resistance identified a non-synonymous mutation in hpaC, resulting in a cysteine substitution at glycine 93. Gc expressing HpaC(Gly93Cys) phenocopied a clean deletion of hpaC with increased SPN resistance. Thus, the point mutation is a loss-of-function mutation. An analysis of the HpaC in almost 1000 Gc isolates from PubMLST [53] showed that HpaC is highly conserved and Gly93 is present in every sequence (S4 Fig). Since an alanine substituted for Gly93 resulted in partial complementation (Fig 3C), the loss-of-function is specific to the cysteine mutation. We tested the effect of HpaC in piliated and nonpiliated Gc and determined that an ΔhpaC mutant increased SPN resistance irrespective of piliation. Interestingly, the HpaC effect was greater in the absence of pilin, suggesting that the T4p interferes with HpaC inhibition of SPN resistance. In H2O2 and LL-37 resistance, the ΔhpaC mutant exhibited increased sensitivity in piliated cells and had no effect in nonpiliated cells. Therefore, we propose that HpaC(Gly93Cys) promotes T4p-independent SPN resistance and enhances T4p-dependent H2O2 and LL-37 sensitivity in Gc (Fig 7).

Fig 7. Model summarizing the HpaC and T4p effects on SPN, LL-37, and H2O2 sensitivity in Gc.

Fig 7

The T4p is required for resistance against SPN, LL-37, and H2O2. HpaC(Gly93Cys) promotes SPN resistance in a T4p-independent manner while promoting LL-37 and H2O2 sensitivity through a mechanism that involves the T4p.

Our results suggest that an HpaC(Gly93Cys) mutation reduces FAD reductase activity. Gly-93 is on a FAD binding loop and mutating this residue alters FAD affinity. We determined that FAD occupancy was higher with an HpaC(Gly93Cys) mutant than WT, indicating that mutating Gly-93 to a cysteine increases FAD affinity for HpaC. Since an HpaC(Gly93Cys) mutant suppressed SPN sensitivity, we hypothesize that the FAD:FADH2 and/or NAD:NADH ratio contributes to SPN sensitivity and a glycine-to-cysteine change disrupts HpaC-dependent FAD reduction. In P. aeruginosa, HpaC binds FAD weakly [48]. Perhaps a low affinity for FAD is important in normal HpaC-mediated reduction. The consequence of enhanced FAD affinity with the HpaC(Gly93Cys) mutant may be an inability of HpaC to dissociate from reduced FAD. Therefore, HpaC(Gly93Cys) does not release FADH2 to donate the electrons to the next cellular effector making HpaC a dead-end for FAD-dependent redox reactions.

There are multiple possible pathways through which HpaC as a flavin reductase can alter SPN, LL-37, and H2O2 sensitivity. Any one of these changes can have a broader impact on the cell. HpaC may affect the level of reactive oxygen species and, thus, sensitivity to oxidative killing. HpaC could affect the level of FADH2 which can spontaneously reduce O2 to H2O2 or enter the electron transport chain and, through sequential, partial reduction of O2, generate superoxide, H2O2, and hydroxyl anions. Indeed, E. coli W HpaC can reduce cytochrome c in vitro, an electron carrier in the respiratory chain [45]. Alternatively, HpaC may impact a flavin-dependent metabolic pathway. Several groups have demonstrated that HpaC in other bacteria supply reduced FAD to the monooxygenase HpaB by diffusion [44,45,49] indicating that no physical interaction is needed. Therefore, reduced flavins from Gc HpaC could indirectly influence sensitivity through FADH2-dependent metabolic enzyme(s).

The genomic context of hpaC suggests that HpaC may be a part of an antimicrobial transcriptional response. hpaC is adjacent to and in the same orientation as the gene farR which suggests they are in an operon. FarR is a transcriptional repressor of the long-chained antimicrobial fatty acids efflux pump FarAB [54,55]. FarR regulates its own expression and is under MtrR (multiple transferable resistance) transcriptional regulation [54]. MtrR also regulates the expression of the pilMNOPQ operon, encoding parts of the T4p secretion system [56]. Therefore, HpaC could be part of the MtrR and FarR transcriptional antimicrobial response that coordinates with piliation status.

Although we have not measured the effect of HpaC on labile intracellular iron in Gc, it is unlikely that HpaC alters intracellular labile iron levels. Elevated iron in nonpiliated cells promotes SPN, LL-37, and H2O2-mediated death [19], but HpaC enhances SPN sensitivity and promotes LL-37 and H2O2 resistance. Therefore, HpaC may affect sensitivity in an iron-independent pathway.

Bioinformatic analysis of other bacterial genomes revealed that, like Neisseria, many bacteria lack the 4-HPA monooxygenase HpaB while encoding HpaC. The phylogenetic distribution of hpaB and hpaC suggests that these genes were present in an early common ancestor(s), and some descendants have lost either the hpaB or hpaC gene. It is possible that HpaB or HpaC function, perhaps in the metabolism of 4-HPA and similar compounds, was deleterious to fitness and, therefore, subject to negative selection. Alternatively, there may be other gene products that substitute for HpaB or HpaC that are not revealed by sequence queries. The function of HpaC in the absence of HpaB or alternative metabolic enzymes is an interesting field for further investigation.

In summary, we characterized a role for HpaC in resistance to SPN, LL-37, and H2O2 in Gc. We predict that it plays an interesting role in other bacteria that is independent of 4-HPA metabolism. To the best of our knowledge, this is the first report of the biological role of HpaC in a context that does not involve HpaB. The impact of HpaC in Gc is linked to its function as an FAD reductase and, given the critical roles that FAD redox has in the cell, HpaC is likely to affect metabolism and energy production.

Materials and methods

Strains and growth

Gc and E. coli strains and plasmids used in the study are listed in Table 1. To control for T4p phase variation, the experiments performed here used an FA1090 strain designated N-1–60 which contains point mutations in the pilE G4 and is pilC2 phase-locked “on” [20]. Plasmids were introduced into Gc by spot transformation [57]. For solid medium, Gc was grown on gonococcal growth broth: 36.25 g/L GC Medium Base (Difco), 1.25 g/L agar, and Kellogg supplements I and II at 37 °C in 5% CO2. For liquid growth, 50 mM sodium bicarbonate and supplement I was added to Gc broth and cells were grown with aeration at 37 °C. Antibiotics and their concentrations used for selection in GCB were kanamycin (Kan) 50 µg/ml and erythromycin (Erm) 1 µg/ml. NEB 5-alpha competent E. coli (High Efficiency) cells used to propagate plasmids and NEB BL21 (DE3) Competent E. coli used to express protein were grown in Luria-Bertani (LB) solid medium containing 15 g/L agar or liquid media at 37 °C. The antibiotics and their concentrations used in LB were ampicillin (Amp) 100 µg/ml and Kan 50 µg/ml.

Mutant construction

hpaC::kan mutant.

An approximately 650 bp fragment containing 270 bases upstream of NGO0059, the first 30 bases of NGO0059, a PacI restriction site, HA tag, NotI restriction site, the last 30 bp of NGO0059, and 270 bp downstream of NGO0059, was synthesized and cloned into pTwist-Amp-MC vector by Twist Biosciences.

A PacI and NotI flanked nptII fragment with a 12-mer DNA uptake sequence at the 3’ end of nptII from a previously generated plasmid [58] was introduced into the PacI- and NotI- digested plasmid from Twist Biosciences in between the upstream and downstream sequences of NGO0059. This plasmid pTwist-hpaC::kan was used to spot transform Gc strains to generate ΔhpaC::kan strains. Transformants were selected on GCB Kan and checked by diagnostic PCR and sequencing.

ΔhpaC::EcoR1-EcoRV-BamH1 polylinker mutant.

We constructed the ΔhpaC::EcoR1-EcoRV-BamH1 mutant by replacing the kanamycin resistance cassette in ΔhpaC::kan with a EcoR1-EcoRV-BamHI (5’-GAATTCGATATCGGATCC-3’) polylinker sequence. To replace the kan cassette in pTwist-hpaC::kan, we ran site-directed mutagenesis on pTwist-hpaC::kan using primers NGO0059_ERB_F (5’-atcggatccAGGCCTTTAGACTGATATTC-3’) and NGO0059_ERB_R (5’-atcgaattcCTGCAAATCCGCCATTTTTC-3’) with Q5 polymerase according to manufacturer protocol (NEB E0554). The DNA mix was treated with a kinase, T4 ligase, and DpnI mix for 5 minutes at room temperature before transformation into NEB 5-alpha Competent E. coli (NEB C2987H). We confirmed the sequence of the fragment from ampicillin resistant clones by Sanger sequencing with primers hpaC_500F (5’-gatgacccaattcaggcctattct-3’) and hpaC_500R (5’- gtcgggcagcagggaaa-3’). The plasmid pTwist-hpaC::EcoR1-EcoRV-BamH1 was spot transformed into ΔhpaC::kan. We screened transformants with Kan sensitivity by PCR and Sanger sequencing to confirm the presence of the polylinker sequence in hpaC, generating the ΔhpaC::EcoR1-EcoRV-BamH1 mutant (N-8–57).

hpaC(Gly93Cys) point mutant.

A 1532 bp PCR product carrying hpaC(Gly93Cys) was generated by using primers NGO0059upF (5’- ATGCCGTCTGAAATACAGGCAAGGGAAGCC-3’) and NGO0059dnR (5’-TGAATGTCAGTCCGTTGCC-3’) from an evolved ΔpilE mutant carrying hpaC(Gly93Cys) and purified using a Qiagen PCR cleanup kit. The PCR product was sent for Sanger sequencing to confirm the presence of the Gly93Cys mutation (G277T nucleotide change) and transformed into CRISPRi-pilE (N-5–22, [27]). We swabbed the cells from the spot into liquid GCBL for SPN selection with IPTG and spread on GCB agar plates. We screened individual colonies for hpaC the G-to-T mutation by PCR and Sanger sequencing.

Complementation strains

We expressed hpaC from the transcriptionally silent lctP-aspC Neisserial intergenic complementation site (nics) [59]. PacI- and PmeI-flanked on the 5’ and 3’ ends of hpaC (NGO0059) was amplified by PCR using primers hpaC_PacI_F (5’-cctTTAATTAAatggcggatttgcagaaaact-3’) and hpaC_PmeI_R (5’-aggGTTTAAACtcagtctaaaggcctaaactgcc-3’) from Gc. After PCR cleanup, the PCR product was cloned into pCR2.1-TOPO vector following manufacturer’s protocol (Invitrogen K450002) resulting in pTOPO-hpaC. We sequenced hpaC using M13F and M13R primers. We amplified hpaC from pTOPO-hpaC with KOD polymerase (Sigma 71085), gel extracted the products, digested the purified PCR product and pGCC4 [59] with PacI and PmeI in rCutsmart buffer (New England Biolabs) for 1 hour at 37 °C, heat inactivated the enzymes for 20 minutes at 65 °C, and ligated the digested PCR product and pGCC4 for 2 hours at room temperature. We transformed the ligation into NEB 5-alpha E. coli (NEB C2987H) or JM109 competent cells (Promega L2005) and selected for Kan (for pGCC4 and pTOPO) resistance and sensitivity to Amp (for pTOPO). We confirmed the insert with Sanger sequencing using primers hpaC_PacI_F and aspCrev (5’-AGTGGAACGAAAACTCACGT-3’). We transformed pGCC4-hpaC plasmid into piliated hpaC null mutants and selected for erythromycin resistance, resulting in the construction of ΔhpaC/nics::hpaC (N-8–53). To construct ΔhpaC/nics::hpaC(Gly93Cys) (N-9–38), we used site-directed mutagenesis of pTOPO-hpaC, sequenced to confirm the presence of the mutation, cloned hpaC(Gly93Cys) into pGCC4, and transformed the plasmid into ΔhpaC (N-8–57). To construct ΔpilEΔhpaC/nics::hpaC (N-8–63), we deleted pilE by screening for nonpiliated colonies after backcrossing genomic DNA from FA1090 ΔpilE (N-1–69) and validating by PCR using primers pilRBS (5’-GGCTTTCCCCTTTCAATTAGGAG-3’) and SP3A (5’-CCGGAACGGACGACCCCG-3’) [20].

Construction of plasmids for HpaC and Gly-93 variant protein expression

The pET28a vector carrying FA1090 hpaC was synthesized (Twist Bioscience) and transformed into BL21 DE3 E. coli cells (Table 1, N-8-3). We performed site-directed mutagenesis (NEB E0554S) on pET28a-FA1090 hpaC to generate pET28a-FA1090 hpaC(Gly93Cys). For Gly93Cys, we used primers FA1090_hpaC_F (5’-CGGGCTGACCTGCCTGTCGCCCG-3’) and reverse primer (5’-GCAAAATGTTCGGCAACATCCTG-3’). We treated the reactions with a kit-provided kinase, T4 ligase, and DpnI mix for 5 minutes at room temperature before transforming 2.5 µl into NEB 5-alpha E. coli (NEB C2987H). After confirmation of the mutation with sequencing, we transformed BL21 DE3 cells and selected for Kan resistance.

In vitro evolution of ΔpilE mutant and backcrossing into CRISPRi-pilE

The pilE clean deletion mutant was grown on GCB agar plates for 16 hours at 37 °C with 5% CO2. Cells were swabbed and inoculated into 15 ml conical tubes containing 1 ml GCBL with supplement I and sodium bicarbonate, shaking for 1.5 hours at 37 °C. The culture was diluted 1:5 with 5 ml GCBL with supplement I and sodium bicarbonate and grew for 1.5 hours at 37 °C. The culture was diluted to an OD550 0.2 and treated with 0.5µM SPN or DMSO for 30 minutes at 37 °C. Cells were pelleted at 4000 rpm for 2 minutes and resuspended in fresh GCBL. Cells were spread onto GCB agar plates, grown overnight at 37 °C with 5% CO2, and stored at -80 °C in GCBL and 20% glycerol and swabbed to enter the next round of growth and selection. The process of growth and selection was repeated six times and relative survival compared to the unevolved ΔpilE mutant was performed three times during the experiment. Genomic DNA was isolated at the sixth round of selection using phenol chloroform extraction and submitted for Illumina sequencing with SeqCenter in Pittsburgh, Pennsylvania. We aligned the reads to the reference sequence N-1–60 (Accession number CP115654.1) and called variants relative to the reference using Snippy v4.6.0 then filtered only for variants that were unique to the evolved isolates (S1 Table).

For isolating the mutations, we spot transformed the gDNA into the CRISPRi-pilE strain (N-5–22) [27]. The patch of cells that were exposed to the gDNA mix was swabbed into GCBL, diluted 1:5 with GCBL with supplement I and sodium bicarbonate and grew for 1.5 hours at 37 °C, cultures were diluted to an OD550 0.05, and grew with and without 1 mM IPTG for 2 hours before treatment with 0.5 µM SPN or DMSO for 30 minutes at 37 °C. Cells were washed by pelleting at 4000 rpm for 2 minutes and resuspending in fresh GCBL. We performed 10-fold dilutions of the cultures onto GCB agar plates and overnight at 37 °C with 5% CO2. Individual colonies were frozen in 100 µl of GCBL with glycerol in 96 well plates. Isolates were tested for SPN sensitivity compared to CRISPRi-pilE in the presence and absence of IPTG. Genomic DNA prepared with phenol chloroform were sent for whole genome sequencing and variant calling with SeqCenter. Sample libraries were prepared using the Illumina DNA Prep kit and IDT 10 bp UDI indices, and sequenced on an Illumina NextSeq 2000, producing 2x151bp reads. Demultiplexing, quality control and adapter trimming was performed with bcl-convert (v3.9.3), a proprietary Illumina software for the conversion of bcl files to basecalls. Variant calling was carried out using Breseq under default settings [60].

Gc antimicrobial killing assays

Cells were grown on GCB agar plates for 16–18 hours at 37 °C with 5% CO2. Individual colonies representing biological replicates were picked and streaked onto GCB agar plates and incubated for 16–18 hours at 37 °C with 5% CO2. Cells were inoculated to an OD550 between 0.2-0.3 in 1 ml GCBL with supplement I and sodium bicarbonate and grew for 1.5 hours at 37 °C. Cultures were diluted 1:5 with 5 ml GCBL with supplement I and sodium bicarbonate and grew for 1.5 at 37 °C. Cultures were diluted to an OD550 0.05 and grown with and without 1 mM IPTG if the strain carries a CRISPR interference array for 1.5-2 hours. The conditions for hydrogen peroxide, LL-37, and SPN killing assays and the method to determine the relative survival then follow the previously described protocol [19].

Complementation

For complementation, we grew Gc to mid-exponential phase, normalized the cultures to an OD550 ~ 0.1, and treated the cultures with or without 12.5 µM IPTG for 1 hour at 37 °C. We then treated piliated FA1090 and ΔhpaC/nics::hpaC (N-1–60 and N-8–53) with 5 µM SPN and nonpiliated ΔpilE and ΔpilE ΔhpaC/nics::hpaC (N-1–69 and N-8–63) 1 µM SPN for 20 minutes at 37 °C.

Purification of FA1090 HpaC and HpaC(Gly93Cys)

A 2.5 ml overnight culture of BL21 DE3/pET28a-FA1090 hpaC or BL21 DE3/pET28a-FA1090 hpaC(Gly93Cys) mutant was diluted into 250 ml LB with kanamycin in a 1 L flask and grew for 2 hours shaking at 37°C. IPTG was added to a final concentration of 0.1 mM and grew overnight with shaking at 37 °C. Cells were pelleted at 4500 rpm at 4°C. The cell pellets were resuspended in 10 ml resuspension buffer (50 mM Tris-HCl, pH 8, 2 mM ethylenediaminetetraacetic acid). Cells were centrifuged and frozen at -80 °C overnight. To lyse the cells, the pellets were resuspended in 25 ml lysis buffer (50 mM NaH2PO4, pH 8, 0.5 M NaCl, 1% triton X-100, with 2 tablets of freshly added cOmplete Mini protease inhibitor, Roche 11836153001) and pulse sonicated for 5 minutes at 35% amplitude in 30 second intervals separated by 20 seconds on ice. Lysates were centrifuged at 4500 rpm at 4°C for 30 minutes. The supernatants were treated with DNase (300 units/25 ml lysate), incubated for 1 hour at room temperature, and passed through a 0.45 µm filter and stored at 4°C. We equilibrated 2.5 ml of cOmplete His-Tag Purification Resin (Roche 5893682001) with 20 column volumes (50 ml) of buffer A (50 mM NaH2PO4, pH 8, 300 mM NaCl). We added the equilibrated resin to the cell lysates and mixed gently overnight at 4°C. We packed the resin-lysate mix by gravity-assisted flow onto a column and the flow-through was collected. We washed the resin with buffer A with 20 mM imidazole and collected the washes in separate tubes for later analysis. We eluted the His-tagged protein with buffer A with 70 mM imidazole into separate fractions and stored the samples at 4°C. We ran the flow-through, washes and elutions on an SDS-PA gel to check the quality of the purification. The most concentrated elution fractions were pooled, diluted to 1 mg/ml, and dialyzed with protein storage buffer (50 mM Tris-HCl, pH 8, 150 mM NaCl, 50% v/v glycerol) overnight at 4°C and stored at -80 °C. We determined the concentration of protein using a BCA kit. We purified 51 µM HpaC and 15 nM HpaC(Gly93Cys).

FAD assays

We used a kit that uses FAD as a cofactor for an oxidase enzyme mix, generating a product that a probe detects, resulting in either fluorescence or a change in color (Abcam ab204710). We used the kit according to manufacturer provided protocol except at room temperature and with half of the recommended OxiRed probe and oxidase enzyme to conserve reagents. Purified His6-tagged FA1090 HpaC or HpaC(Gly93Cys) was denatured by heating at 95 °C for 5 minutes or not, cooled on ice, and added to the FAD assay reactions in black polystyrene 96-well assay plates (costar 3915). Fluorescence was measured every two minutes with excitation and emission maxima of 535/587 nm.

Aligning FA1090 HpaC to B. cepacia TftC

We aligned the peptide sequence of FA1090 HpaC to TftC from B. cepacia (PDB 3K88). We used the “align” command in PyMOL with five refinement cycles for outlier rejection. The analysis yielded an alignment with a root mean square deviation (RMSD) 0.684 Å for the backbone Cα atoms.

Bioinformatic analysis of bacterial genomes containing hpaB and/or hpaC

We searched for the terms “hpaC” and “hpaB” on the National Center for Biotechnology Institute Gene database [50], accessed each genus listed in the taxonomic groups of Betaproteobacteria (26 genera) and Gammaproteobacteria (57 genera), confirmed the presence of HpaC and HpaB by protein sequence homology, and analyzed the genomic context surrounding either hpaC or hpaB (~10 genes up or downstream) to identify if the other gene was present. We manually curated the genera into categories of genomes having either hpaC, hpaB, or both. After ClustalW alignment of the 16S rRNA sequences, we generated neighbor-joining rooted phylogenetic trees in Jalview.

Supporting information

S1 Fig. Concentration-dependent HpaC involvement in LL-37 and hydrogen peroxide resistance.

Relative survival of FA1090 (N-1–60), ΔhpaC::ERB (N-8–59), ΔpilE (N-1–69), and ΔpilEΔhpaC (N-8–61) to LL-37 (A and B) and hydrogen peroxide (C and D). A one-way ANOVA was used to determine statistical significance. The means and SEMs are plotted for biological replicates.

(TIF)

ppat.1013607.s001.tif (366.4KB, tif)
S2 Fig. HpaC has no significant effect on other antibiotic sensitivities.

The minimum inhibitory concentrations for six antimicrobials were determined using E-test strips (µg/ml). Three biological replicates of the parental strain (N-1–60) and isogenic mutants ΔpilE (N-1–69), ΔhpaC (N-8–59), and a double mutant ΔpilEΔhpaC (N-8–61) were tested. Statistical significance was determined by a one-way ANOVA followed by a Sidak’s multiple comparisons test.

(TIF)

ppat.1013607.s002.tif (262.3KB, tif)
S3 Fig. The effect of antioxidant tiron (0.5 mM) on streptonigrin (1 µM) sensitivity in the absence of PilE (ΔpilE, N-1–69) or without both PilE and HpaC (ΔpilE ΔhpaC, N-7–52).

Average relative survival is shown with standard error of the mean for six biological replicates. A 2way ANOVA followed by a Dunnett’s multiple comparisons test was used to determine statistical significance.

(TIF)

ppat.1013607.s003.tif (138.3KB, tif)
S4 Fig. Structural modeling of FA1090 HpaC.

A) Overlay of B. cepacia TftC (PDB 3K88 in cyan) and FA1090 HpaC (red). Glycine-93 is highlighted in orange. B-D) FA1090 HpaC modeled with FAD (purple) and NADH (green) and the two conserved FAD binding loops (white). HpaC from B is rotated 90° to the right (C) or 90° up (D) to show different perspectives of the FAD binding pocket. E) N. gonorrhoeae HpaC consensus logo sequence. A consensus sequence of 999 NEIS0375 HpaC homologs with a peptide sequence of 166 residues from PubMLST using weblogo.berkley.edu. Underlined are the two conserved FAD binding loops. Marked with an asterisk is amino acid residue 93.

(TIF)

ppat.1013607.s004.tif (1.2MB, tif)
S1 Table. Genetic differences in streptonigrin resistant ΔpilE mutant.

After in vitro evolution, reads from whole genome sequencing were aligned to an unevolved reference strain N-1–60 [19] and variants unique to the evolved ΔpilE mutant were called.

(PDF)

ppat.1013607.s005.pdf (144.6KB, pdf)

Acknowledgments

The authors thank the current and past members of the Seifert lab for their insight and support. In particular, we thank Drs. Selma Metaane for her valuable feedback of the manuscript and Wendy Geslewitz for her thoughtful conversations on this work.

Data Availability

The data that support the findings of this study are publicly available from Prism with the identifier DOI https://doi.org/10.18131/rv6c4-rdb68.

Funding Statement

This work was supported by National Institute of Allergy and Infectious Diseases (https://www.niaid.nih.gov/) grants R01 AI146073 and R21 AI148981 to HSS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This manuscript is the result of funding in whole or in part by the National Institutes of Health (NIH). It is subject to the NIH Public Access Policy. Through acceptance of this federal funding, NIH has been given a right to make this manuscript publicly available in PubMed Central upon the Official Date of Publication, as defined by NIH.

References

  • 1.Walker CK, Sweet RL. Gonorrhea infection in women: prevalence, effects, screening, and management. Int J Womens Health. 2011;3:197–206. doi: 10.2147/IJWH.S13427 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Bardin T. Gonococcal arthritis. Best Pract Res Clin Rheumatol. 2003;17(2):201–8. doi: 10.1016/s1521-6942(02)00125-0 [DOI] [PubMed] [Google Scholar]
  • 3.Thiéry G, Tankovic J, Brun-Buisson C, Blot F. Gonococcemia associated with fatal septic shock. Clin Infect Dis. 2001;32(5):E92-3. doi: 10.1086/319204 [DOI] [PubMed] [Google Scholar]
  • 4.Woods CR. Gonococcal infections in neonates and young children. Semin Pediatr Infect Dis. 2005;16(4):258–70. doi: 10.1053/j.spid.2005.06.006 [DOI] [PubMed] [Google Scholar]
  • 5.Escobar A, Rodas PI, Acuña-Castillo C. Macrophage-Neisseria gonorrhoeae Interactions: A Better Understanding of Pathogen Mechanisms of Immunomodulation. Front Immunol. 2018;9:3044. doi: 10.3389/fimmu.2018.03044 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Kaparakis M, Turnbull L, Carneiro L, Firth S, Coleman HA, Parkington HC, et al. Bacterial membrane vesicles deliver peptidoglycan to NOD1 in epithelial cells. Cell Microbiol. 2010;12(3):372–85. doi: 10.1111/j.1462-5822.2009.01404.x [DOI] [PubMed] [Google Scholar]
  • 7.Sintsova A, Sarantis H, Islam EA, Sun CX, Amin M, Chan CHF, et al. Global analysis of neutrophil responses to Neisseria gonorrhoeae reveals a self-propagating inflammatory program. PLoS Pathog. 2014;10(9):e1004341. doi: 10.1371/journal.ppat.1004341 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol. 2004;4(3):181–9. doi: 10.1038/nri1312 [DOI] [PubMed] [Google Scholar]
  • 9.Liew PX, Kubes P. The Neutrophil’s Role During Health and Disease. Physiol Rev. 2019;99(2):1223–48. doi: 10.1152/physrev.00012.2018 [DOI] [PubMed] [Google Scholar]
  • 10.Lei J, Sun L, Huang S, Zhu C, Li P, He J, et al. The antimicrobial peptides and their potential clinical applications. Am J Transl Res. 2019;11(7):3919–31. [PMC free article] [PubMed] [Google Scholar]
  • 11.Criss AK, Seifert HS. A bacterial siren song: intimate interactions between Neisseria and neutrophils. Nat Rev Microbiol. 2012;10(3):178–90. doi: 10.1038/nrmicro2713 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Stohl EA, Criss AK, Seifert HS. The transcriptome response of Neisseria gonorrhoeae to hydrogen peroxide reveals genes with previously uncharacterized roles in oxidative damage protection. Mol Microbiol. 2005;58(2):520–32. doi: 10.1111/j.1365-2958.2005.04839.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Criss AK, Seifert HS. Neisseria gonorrhoeae suppresses the oxidative burst of human polymorphonuclear leukocytes. Cell Microbiol. 2008;10(11):2257–70. doi: 10.1111/j.1462-5822.2008.01205.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Gunderson CW, Seifert HS. Neisseria gonorrhoeae elicits extracellular traps in primary neutrophil culture while suppressing the oxidative burst. mBio. 2015;6(1):e02452-14. doi: 10.1128/mBio.02452-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Criss AK, Katz BZ, Seifert HS. Resistance of Neisseria gonorrhoeae to non-oxidative killing by adherent human polymorphonuclear leucocytes. Cell Microbiol. 2009;11(7):1074–87. doi: 10.1111/j.1462-5822.2009.01308.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Johnson MB, Criss AK. Resistance of Neisseria gonorrhoeae to neutrophils. Front Microbiol. 2011;2:77. doi: 10.3389/fmicb.2011.00077 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Soler-García AA, Jerse AE. A Neisseria gonorrhoeae catalase mutant is more sensitive to hydrogen peroxide and paraquat, an inducer of toxic oxygen radicals. Microb Pathog. 2004;37(2):55–63. doi: 10.1016/j.micpath.2004.04.007 [DOI] [PubMed] [Google Scholar]
  • 18.Gunesekere IC, Kahler CM, Ryan CS, Snyder LAS, Saunders NJ, Rood JI, et al. Ecf, an alternative sigma factor from Neisseria gonorrhoeae, controls expression of msrAB, which encodes methionine sulfoxide reductase. J Bacteriol. 2006;188(10):3463–9. doi: 10.1128/JB.188.10.3463-3469.2006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Hu LI, Stohl EA, Seifert HS. The Neisseria gonorrhoeae type IV pilus promotes resistance to hydrogen peroxide- and LL-37-mediated killing by modulating the availability of intracellular, labile iron. PLoS Pathog. 2022;18(6):e1010561. doi: 10.1371/journal.ppat.1010561 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Seifert HS, Wright CJ, Jerse AE, Cohen MS, Cannon JG. Multiple gonococcal pilin antigenic variants are produced during experimental human infections. J Clin Invest. 1994;93(6):2744–9. doi: 10.1172/JCI117290 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Swanson J, Robbins K, Barrera O, Corwin D, Boslego J, Ciak J, et al. Gonococcal pilin variants in experimental gonorrhea. J Exp Med. 1987;165(5):1344–57. doi: 10.1084/jem.165.5.1344 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Merz AJ, So M, Sheetz MP. Pilus retraction powers bacterial twitching motility. Nature. 2000;407(6800):98–102. doi: 10.1038/35024105 [DOI] [PubMed] [Google Scholar]
  • 23.Higashi DL, Lee SW, Snyder A, Weyand NJ, Bakke A, So M. Dynamics of Neisseria gonorrhoeae attachment: microcolony development, cortical plaque formation, and cytoprotection. Infect Immun. 2007;75(10):4743–53. doi: 10.1128/IAI.00687-07 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Chen I, Dubnau D. DNA uptake during bacterial transformation. Nat Rev Microbiol. 2004;2(3):241–9. doi: 10.1038/nrmicro844 [DOI] [PubMed] [Google Scholar]
  • 25.Stohl EA, Dale EM, Criss AK, Seifert HS. Neisseria gonorrhoeae metalloprotease NGO1686 is required for full piliation, and piliation is required for resistance to H2O2- and neutrophil-mediated killing. mBio. 2013;4(4):e00399-13. doi: 10.1128/mBio.00399-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Gupta A, Imlay JA. How a natural antibiotic uses oxidative stress to kill oxidant-resistant bacteria. Proc Natl Acad Sci U S A. 2023;120(52):e2312110120. doi: 10.1073/pnas.2312110120 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Geslewitz WE, Cardenas A, Zhou X, Zhang Y, Criss AK, Seifert HS. Development and implementation of a Type I-C CRISPR-based programmable repression system for Neisseria gonorrhoeae. mBio. 2024;15(2):e0302523. doi: 10.1128/mbio.03025-23 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Zelewska MA, Pulijala M, Spencer-Smith R, Mahmood H-T-NA, Norman B, Churchward CP, et al. Phase variable DNA repeats in Neisseria gonorrhoeae influence transcription, translation, and protein sequence variation. Microb Genom. 2016;2(8):e000078. doi: 10.1099/mgen.0.000078 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Shafer WM, Datta A, Kolli VSK, Rahman MM, Balthazar JT, Martin LE, et al. Phase variable changes in genes lgtA and lgtC within the lgtABCDE operon of Neisseria gonorrhoeae can modulate gonococcal susceptibility to normal human serum. J Endotoxin Res. 2002;8(1):47–58. doi: 10.1177/09680519020080010501 [DOI] [PubMed] [Google Scholar]
  • 30.Carson SD, Stone B, Beucher M, Fu J, Sparling PF. Phase variation of the gonococcal siderophore receptor FetA. Mol Microbiol. 2000;36(3):585–93. doi: 10.1046/j.1365-2958.2000.01873.x [DOI] [PubMed] [Google Scholar]
  • 31.Cohen MS, Chai Y, Britigan BE, McKenna W, Adams J, Svendsen T, et al. Role of extracellular iron in the action of the quinone antibiotic streptonigrin: mechanisms of killing and resistance of Neisseria gonorrhoeae. Antimicrob Agents Chemother. 1987;31(10):1507–13. doi: 10.1128/AAC.31.10.1507 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Ledenev AN, Konstantinov AA, Popova E, Ruuge EK. A simple assay of the superoxide generation rate with Tiron as an EPR-visible radical scavenger. Biochem Int. 1986;13(2):391–6. [PubMed] [Google Scholar]
  • 33.Webb BN, Ballinger JW, Kim E, Belchik SM, Lam K-S, Youn B, et al. Characterization of chlorophenol 4-monooxygenase (TftD) and NADH:FAD oxidoreductase (TftC) of Burkholderia cepacia AC1100. J Biol Chem. 2010;285(3):2014–27. doi: 10.1074/jbc.M109.056135 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Wang J, Lonergan ZR, Gonzalez-Gutierrez G, Nairn BL, Maxwell CN, Zhang Y. Multi-metal restriction by calprotectin impacts de novo flavin biosynthesis in Acinetobacter baumannii. Cell Chemical Biology. 2019;26(5):745-755 e7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Yang K, Zhang QC, Zhao WR, Hu S, Lv CJ, Huang J. Advances in 4-hydroxyphenylacetate-3-hydroxylase monooxygenase. Molecules. 2023;28(18). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Takahama U, Oniki T, Murata H. The presence of 4-hydroxyphenylacetic acid in human saliva and the possibility of its nitration by salivary nitrite in the stomach. FEBS Lett. 2002;518(1–3):116–8. doi: 10.1016/s0014-5793(02)02659-5 [DOI] [PubMed] [Google Scholar]
  • 37.Sun P, Xu SP, Tian Y, Chen PC, Wu D, Zheng P. 4-Hydroxyphenylacetate 3-Hydroxylase (4HPA3H): A Vigorous Monooxygenase for Versatile O-Hydroxylation Applications in the Biosynthesis of Phenolic Derivatives. Int J Mol Sci. 2024;25(2). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Chaiyen P, Suadee C, Wilairat P. A novel two-protein component flavoprotein hydroxylase: p-hydroxyphenylacetate hydroxylase from Acinetobacter baumanii. Eur J Biochem. 2001;268(21):5550–61. [DOI] [PubMed] [Google Scholar]
  • 39.Kim S-H, Hisano T, Iwasaki W, Ebihara A, Miki K. Crystal structure of the flavin reductase component (HpaC) of 4-hydroxyphenylacetate 3-monooxygenase from Thermus thermophilus HB8: Structural basis for the flavin affinity. Proteins. 2008;70(3):718–30. doi: 10.1002/prot.21534 [DOI] [PubMed] [Google Scholar]
  • 40.Kim S-H, Hisano T, Takeda K, Iwasaki W, Ebihara A, Miki K. Crystal structure of the oxygenase component (HpaB) of the 4-hydroxyphenylacetate 3-monooxygenase from Thermus thermophilus HB8. J Biol Chem. 2007;282(45):33107–17. doi: 10.1074/jbc.M703440200 [DOI] [PubMed] [Google Scholar]
  • 41.Furuya T, Kino K. Catalytic activity of the two-component flavin-dependent monooxygenase from Pseudomonas aeruginosa toward cinnamic acid derivatives. Appl Microbiol Biotechnol. 2014;98(3):1145–54. doi: 10.1007/s00253-013-4958-y [DOI] [PubMed] [Google Scholar]
  • 42.Arias-Barrau E, Sandoval A, Naharro G, Olivera ER, Luengo JM. A two-component hydroxylase involved in the assimilation of 3-hydroxyphenyl acetate in Pseudomonas putida. J Biol Chem. 2005;280(28):26435–47. doi: 10.1074/jbc.M501988200 [DOI] [PubMed] [Google Scholar]
  • 43.Gibello A, Ferrer E, Sanz J, Martin M. Polymer production by Klebsiella pneumoniae 4-hydroxyphenylacetic acid hydroxylase genes cloned in Escherichia coli. Appl Environ Microbiol. 1995;61(12):4167–71. doi: 10.1128/aem.61.12.4167-4171.1995 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Xun L, Sandvik ER. Characterization of 4-hydroxyphenylacetate 3-hydroxylase (HpaB) of Escherichia coli as a reduced flavin adenine dinucleotide-utilizing monooxygenase. Appl Environ Microbiol. 2000;66(2):481–6. doi: 10.1128/AEM.66.2.481-486.2000 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Galán B, Díaz E, Prieto MA, García JL. Functional analysis of the small component of the 4-hydroxyphenylacetate 3-monooxygenase of Escherichia coli W: a prototype of a new Flavin:NAD(P)H reductase subfamily. J Bacteriol. 2000;182(3):627–36. doi: 10.1128/JB.182.3.627-636.2000 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Arunachalam U, Massey V, Miller SM. Mechanism of p-hydroxyphenylacetate-3-hydroxylase. A two-protein enzyme. J Biol Chem. 1994;269(1):150–5. doi: 10.1016/s0021-9258(17)42327-1 [DOI] [PubMed] [Google Scholar]
  • 47.Sucharitakul J, Phongsak T, Entsch B, Svasti J, Chaiyen P, Ballou DP. Kinetics of a two-component p-hydroxyphenylacetate hydroxylase explain how reduced flavin is transferred from the reductase to the oxygenase. Biochemistry. 2007;46(29):8611–23. doi: 10.1021/bi7006614 [DOI] [PubMed] [Google Scholar]
  • 48.Chakraborty S, Ortiz-Maldonado M, Entsch B, Ballou DP. Studies on the mechanism of p-hydroxyphenylacetate 3-hydroxylase from Pseudomonas aeruginosa: a system composed of a small flavin reductase and a large flavin-dependent oxygenase. Biochemistry. 2010;49(2):372–85. doi: 10.1021/bi901454u [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Louie TM, Xie XS, Xun L. Coordinated production and utilization of FADH2 by NAD(P)H-flavin oxidoreductase and 4-hydroxyphenylacetate 3-monooxygenase. Biochemistry. 2003;42(24):7509–17. doi: 10.1021/bi034092r [DOI] [PubMed] [Google Scholar]
  • 50.Gene Help [Internet]. Bethesda (MD): National Center for Biotechnology Information (US) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2008 Apr 21 [updated 2018 Apr 9]. https://www.ncbi.nlm.nih.gov/books/NBK3840/
  • 51.Prieto MA, Perez-Aranda A, Garcia JL. Characterization of an Escherichia coli aromatic hydroxylase with a broad substrate range. J Bacteriol. 1993;175(7):2162–7. doi: 10.1128/jb.175.7.2162-2167.1993 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Cooper RA, Skinner MA. Catabolism of 3- and 4-hydroxyphenylacetate by the 3,4-dihydroxyphenylacetate pathway in Escherichia coli. J Bacteriol. 1980;143(1):302–6. doi: 10.1128/jb.143.1.302-306.1980 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Jolley KA, Bray JE, Maiden MCJ. Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications. Wellcome Open Res. 2018;3:124. doi: 10.12688/wellcomeopenres.14826.1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Lee E-H, Rouquette-Loughlin C, Folster JP, Shafer WM. FarR regulates the farAB-encoded efflux pump of Neisseria gonorrhoeae via an MtrR regulatory mechanism. J Bacteriol. 2003;185(24):7145–52. doi: 10.1128/JB.185.24.7145-7152.2003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Lee EH, Shafer WM. The farAB-encoded efflux pump mediates resistance of gonococci to long-chained antibacterial fatty acids. Mol Microbiol. 1999;33(4):839–45. doi: 10.1046/j.1365-2958.1999.01530.x [DOI] [PubMed] [Google Scholar]
  • 56.Folster JP, Dhulipala V, Nicholas RA, Shafer WM. Differential regulation of ponA and pilMNOPQ expression by the MtrR transcriptional regulatory protein in Neisseria gonorrhoeae. J Bacteriol. 2007;189(13):4569–77. doi: 10.1128/JB.00286-07 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Dillard JP, Chan JM. Genetic Manipulation of Neisseria gonorrhoeae and Commensal Neisseria Species. Curr Protoc. 2024;4(9):e70000. doi: 10.1002/cpz1.70000 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Hu LI, Yin S, Ozer EA, Sewell L, Rehman S, Garnett JA. Discovery of a New Neisseria gonorrhoeae Type IV Pilus Assembly Factor, TfpC. Mbio. 2020;11(5). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Mehr IJ, Seifert HS. Differential roles of homologous recombination pathways in Neisseria gonorrhoeae pilin antigenic variation, DNA transformation and DNA repair. Mol Microbiol. 1998;30(4):697–710. doi: 10.1046/j.1365-2958.1998.01089.x [DOI] [PubMed] [Google Scholar]
  • 60.Deatherage DE, Barrick JE. Identification of mutations in laboratory-evolved microbes from next-generation sequencing data using breseq. Methods Mol Biol. 2014;1151:165–88. doi: 10.1007/978-1-4939-0554-6_12 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

William M Shafer, D Scott Samuels

22 Aug 2025

PPATHOGENS-D-25-01885

The flavin reductase HpaC differentially sensitizes Neisseria gonorrhoeae during Type IV pilus-dependent killing

PLOS Pathogens

Dear Dr Hu,

Thank you for submitting your manuscript to PLOS Pathogens. Your manuscript has been evaluated by members of the editorial board and three external referees. All three reviewers expressed positive comments about the manuscript. They do, however, have comments that need attention with appropriate editorial changes (see below). Note that additional experiments are not required. Upon receipt of the revised manuscript with an accompanying response to each comment a final decision will be possible. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript within 30 days Oct 21 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plospathogens@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/ppathogens/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

* A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. This file does not need to include responses to any formatting updates and technical items listed in the 'Journal Requirements' section below.

* A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

* An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

William M Shafer, Ph.D.

Guest Editor

PLOS Pathogens

D. Scott Samuels

Section Editor

PLOS Pathogens

Sumita Bhaduri-McIntosh

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0003-2946-9497

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

Journal Requirements:

1) We ask that a manuscript source file is provided at Revision. Please upload your manuscript file as a .doc, .docx, .rtf or .tex. If you are providing a .tex file, please upload it under the item type u2018LaTeX Source Fileu2019 and leave your .pdf version as the item type u2018Manuscriptu2019.

2) Please ensure that the funders and grant numbers match between the Financial Disclosure field and the Funding Information tab in your submission form. Note that the funders must be provided in the same order in both places as well.

State what role the funders took in the study. If the funders had no role in your study, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.".

If you did not receive any funding for this study, please simply state: u201cThe authors received no specific funding for this work.u201d

Reviewers' Comments:

Reviewer's Responses to Questions

Part I - Summary

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer #1: The strength of the study was use of superior genetic technology iCRISP to induce or suppress gene expression in concert with other mutagenesis technology to thoroughly characterise the role of HpaC in resistance phenotypes towards oxidative stress and antimicrobial peptides.

The novelty was derived from finding the involvement of a flavin reductase in antibiotic resistance in Neisseria.

The weaknesses were minor. I think that the model presented in Figure 5 could be improved as it is known that mtrR regulates pili expression and farA and could be incorporated.

This was a well written and cited article and raised no concerns for me.

Reviewer #2: This is an interesting paper describing the findings of an in vitro evolution experiment looking for the basis of SPN sensitivity in the goncococus (Gc). The authors identify a SNP in HpaC which they show convincingly affect SPN sensitivity in a T4p-independent manner. Interestingly the authors show that Gc have an orphan HpaC (i.e. present without HpaB), which is a previously unappreciate feature of other bacteria. The SNP phenocopies a HpaC null mutant in its sensitivity to antimicrobials and the role of T4p. Quite how this occurs is not clear, although they provide evidence that the SNP enhances the interaction between FAD and the recombinant protein. The mechanism of action of HpaC's invovlement in resistant is not defined in this paper, and I think it is beyond the scope of the current manuscript.

The Figures are well presented and findings justify the conclusions. The paper is well written but there are areas that would benefit from clarification.

Reviewer #3: Hu et al. describe the in vitro evolution of N. gonorrhoeae pilE mutants to identify loci involved in streptonigrin sensitivity. A mutation was found in hapC, encoding an FAD reductase. pilE and hpaC mutants and double mutants were analyzed for effects on hydrogen peroxide-, antibiotic-, and LL-37 resistance. The results add to our understanding of the ways that type IV pili are involved in providing hydrogen peroxide and antimicrobial peptide resistance.

The description of the identification of the hpaC mutation and the analyses of the mutants is straightforward and readily understandable. That is helpful to the reader for understanding this complex system.

**********

Part II – Major Issues: Key Experiments Required for Acceptance

Please use this section to detail the key new experiments or modifications of existing experiments that should be absolutely required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a "Major Revision" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend "Reject".

Reviewer #1: In the discussion (line 317-322), the authors postulate that the FAD reductase HpaC could be co-expressed with the known antibiotic resistance regulator, FarR, in an operon. FarR itself is regulated by the antibiotic resistance regulator MtrR which has also been shown to regulate pili expression (J Bacteriol. 2007 May 4;189(13):4569–4577). I feel that if the authors could show that HpaC and FarR are in an operon, they can improve the sophistication of their model in Figure 5 by incorporating the known regulatory pathway of mtrR controlling both pili expression and HpaC. I feel this would improve the impact of the paper,

Reviewer #2: I dont have any experiments that need doing.

However, it would be interesting to search Gc genome databases to examine naturally occurring polymorphisms in HpaC, and see if any map to similar sites or might be predicted to give a loss of function.

Reviewer #3: No experiments required.

It is not quite convincing that the hpaC pilE double mutant is not different from the pilE and hpaC single mutants for H2O2 resistance (Fig 4B). The authors should tone down their claims of no effect in the double mutant in lines 193 and 284.

**********

Part III – Minor Issues: Editorial and Data Presentation Modifications

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer #1: In Figure 1 panel C, I think the last two panels are mislabelled as T1 and T2 and are meant to be T3 and T4.

Table 3 and 4: I do prefer to see this information in phylogenetic trees as they are usually more visually memorable than a Table. This is not an essential suggestion but it could look better in the final publication.

FAD reductases have known roles in antibiotic resistance, the most well known of these being the flavin reductases involved in metronidazole sensitivity. To help with the global impact of the observation made here I would have liked to see some mention of this as it would draw readers from other areas and not just Neisseria.

Reviewer #2: I suggest that the authors are more careful with the title, and also the summary figure. The authors do not demonstrate that HpaC is a flavin reductase. They might think this is the case, and could strengthen this by more careful comparison of its predicted structure with characterized related enzymes. However in the absence of biochemical data, they shouldnt state this in the title based on the evidence presented in the article, and the summary figure should include a ?mark.

I think T3 and T4 are incorrectly labeled in Fig 1C as T1 and T2 (again). Also change 'treated with SPRN' to 'backcrossed with SPNR' as it sounds like the gDNA was in the assay. And based on genome sequencing are T3 and T4 identical? If so, say so.

The discussion/analysis of the Alphafold models should be improved. What are the active site residues in this class of enzymes? Are they conserved in Gc? These sies should be shown zoomed in. They should overlay the known and predicted structures to give confidence to the reader of how closely related they are. How often were simulations run? Where is the substitution in relation to FAD? A single view of the structure is not helpful.

Authors should be careful re the use of the term binding affinities or binding when affinities/interaction alone would be sufficient as it includes off as well as on rates during the association of the protein with its substrate. For example, the substitution could trap the product (assumed to be FADH2) or indeed limit catalysis so increase association with the substrate. Neither of these mechanisms affect binding per se.

The authors should discuss why the screen did not identify HpaC loss of function nonsense mutants. These should be much more common than a non-synonymous SNP that alters protein function.

Tables 3/4 The parameters of searches should be described in detail (ie protein or nucleotide, cutoffs for identity/similarity and for %coverage, whether they were reiterative, of what databases specifically etc). In this way, it will be clear to the reader whether the absence of HpaB is correct or is due to searches performed with excessive stringency.

Minor comments:

l61 opacity proteins

l69 which neutrophil membrane

l134/Fig 1C I dont think it is correct that the 'two transformants... were more resistant to SPN when we repressed pilE than without repression'. The relative surivival of both mutants went down on repression of pilE. This sentence could be split in two.

Reviewer #3: 1. Line 52. Delete the word “main”. Gc is the only cause of “gonorrhea”.

2. Line 53. Correct to “second leading bacterial sexually transmitted infection…”. Viral STIs are more common.

3. Line 59. While the sentence about macrophage PRRs responding to Gc peptidoglycan and OM components is correct, it leaves the impression that those are the only cells responding. Epithelial cells also respond to those components and call for the neutrophil infiltration.

4. Line 78. It is the pilus that is assembled and disassembled, whereas this sentence makes it sound like the PilE protein is being taken apart. Reword.

5. Lines 100-101. It is 1/100 to 1/1000 pilE Gc that survive SPN, not that many that are killed. Similarly, it is 1/10 WT Gc that survive SPN.

6. Line 110. It seems odd that adjacent genes lgtC and lgtD would have such different NGO numbers, since the genes were numbered by chromosomal location. Can NGO11620 really be the gene next to NGO2158. Check the numbers.

7. Lines 134-136. This sentence is ambiguous in terms of what two values are being compared (pilE repressed vs unrepressed or resistance between mutants). I know they meant the latter, but the sentence is confusing and imprecise.

8. Line 148. Spell “pilE”.

9. Line 178. Since the authors used IPTG to repress genes (through CRISPRi) in the previous figures, it would be helpful to indicate in the legend or the figure (Fig. 3) that IPTG is being used to induce expression of the hpaC complement in this experiment.

10. The label in Fig. 1C is probably meant to read “T1, T2, T3, T4”.

11. The legend for the model would be more helpful if it was more descriptive of the figure and the conclusions of the study. Also, what are the blue dots supposed to represent?

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

Figure resubmission:

After uploading your figures to PLOS’s NAAS tool - https://ngplosjournals.pagemajik.ai/artanalysis, NAAS will process the files provided and display the results in the "Uploaded Files" section of the page as the processing is complete. If the uploaded figures meet our requirements (or NAAS is able to fix the files to meet our requirements), the figure will be marked as "fixed" above. If NAAS is unable to fix the files, a red "failed" label will appear above. When NAAS has confirmed that the figure files meet our requirements, please download the file via the download option, and include these NAAS processed figure files when submitting your revised manuscript.

Reproducibility:

To enhance the reproducibility of your results, we recommend that authors of applicable studies deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Decision Letter 1

William M Shafer, D Scott Samuels

9 Oct 2025

Dear Dr. Hu,

We are pleased to inform you that your manuscript 'Flavin affinity for the reductase HpaC differentially sensitizes Neisseria gonorrhoeae during Type IV pilus-dependent killing' has been provisionally accepted for publication in PLOS Pathogens.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

William M Shafer, Ph.D.

Guest Editor

PLOS Pathogens

D. Scott Samuels

Section Editor

PLOS Pathogens

Sumita Bhaduri-McIntosh

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0003-2946-9497

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

Acceptance letter

William M Shafer, D Scott Samuels

Dear Dr. Hu,

We are delighted to inform you that your manuscript, "Flavin affinity for the reductase HpaC differentially sensitizes Neisseria gonorrhoeae during Type IV pilus-dependent killing," has been formally accepted for publication in PLOS Pathogens.

We have now passed your article onto the PLOS Production Department who will complete the rest of the pre-publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Pearls, Reviews, Opinions, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript, if you opted to have an early version of your article, will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

For Research Articles, you will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Sumita Bhaduri-McIntosh

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0003-2946-9497

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Concentration-dependent HpaC involvement in LL-37 and hydrogen peroxide resistance.

    Relative survival of FA1090 (N-1–60), ΔhpaC::ERB (N-8–59), ΔpilE (N-1–69), and ΔpilEΔhpaC (N-8–61) to LL-37 (A and B) and hydrogen peroxide (C and D). A one-way ANOVA was used to determine statistical significance. The means and SEMs are plotted for biological replicates.

    (TIF)

    ppat.1013607.s001.tif (366.4KB, tif)
    S2 Fig. HpaC has no significant effect on other antibiotic sensitivities.

    The minimum inhibitory concentrations for six antimicrobials were determined using E-test strips (µg/ml). Three biological replicates of the parental strain (N-1–60) and isogenic mutants ΔpilE (N-1–69), ΔhpaC (N-8–59), and a double mutant ΔpilEΔhpaC (N-8–61) were tested. Statistical significance was determined by a one-way ANOVA followed by a Sidak’s multiple comparisons test.

    (TIF)

    ppat.1013607.s002.tif (262.3KB, tif)
    S3 Fig. The effect of antioxidant tiron (0.5 mM) on streptonigrin (1 µM) sensitivity in the absence of PilE (ΔpilE, N-1–69) or without both PilE and HpaC (ΔpilE ΔhpaC, N-7–52).

    Average relative survival is shown with standard error of the mean for six biological replicates. A 2way ANOVA followed by a Dunnett’s multiple comparisons test was used to determine statistical significance.

    (TIF)

    ppat.1013607.s003.tif (138.3KB, tif)
    S4 Fig. Structural modeling of FA1090 HpaC.

    A) Overlay of B. cepacia TftC (PDB 3K88 in cyan) and FA1090 HpaC (red). Glycine-93 is highlighted in orange. B-D) FA1090 HpaC modeled with FAD (purple) and NADH (green) and the two conserved FAD binding loops (white). HpaC from B is rotated 90° to the right (C) or 90° up (D) to show different perspectives of the FAD binding pocket. E) N. gonorrhoeae HpaC consensus logo sequence. A consensus sequence of 999 NEIS0375 HpaC homologs with a peptide sequence of 166 residues from PubMLST using weblogo.berkley.edu. Underlined are the two conserved FAD binding loops. Marked with an asterisk is amino acid residue 93.

    (TIF)

    ppat.1013607.s004.tif (1.2MB, tif)
    S1 Table. Genetic differences in streptonigrin resistant ΔpilE mutant.

    After in vitro evolution, reads from whole genome sequencing were aligned to an unevolved reference strain N-1–60 [19] and variants unique to the evolved ΔpilE mutant were called.

    (PDF)

    ppat.1013607.s005.pdf (144.6KB, pdf)
    Attachment

    Submitted filename: Response_to_Reviewers.pdf

    ppat.1013607.s007.pdf (157.7KB, pdf)

    Data Availability Statement

    The data that support the findings of this study are publicly available from Prism with the identifier DOI https://doi.org/10.18131/rv6c4-rdb68.


    Articles from PLOS Pathogens are provided here courtesy of PLOS

    RESOURCES